NCT03053635View on ClinicalTrials.gov

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 21, 2016

Primary Completion Date

August 9, 2018

Study Completion Date

August 9, 2018

Conditions
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Interventions
DRUG

TLD1433 infusion and photodynamic therapy (PDT) treatment

TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).

Trial Locations (1)

M5G 2C4

University Health Network, Toronto

Sponsors

Collaborators (2)

Medelis Inc.
WCCT Global
All Listed Sponsors
collaborator

University Health Network, Toronto

OTHER

collaborator

Medelis Inc.

INDUSTRY

collaborator

WCCT Global

INDUSTRY

lead

Theralase® Technologies Inc.

INDUSTRY

NCT03053635 - Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients | Biotech Hunter | Biotech Hunter